Cerus is a biomedical company that develops and commercializes the INTERCEPT Blood System, a proprietary pathogen reduction technology that inactivates viruses, bacteria, parasites, and other pathogens in donated blood components intended for transfusion while preserving their therapeutic properties. The company sells INTERCEPT systems for platelets, plasma, and fibrinogen concentrate through direct sales forces and distributors to blood centers, hospitals, and transfusion services globally, with the U.S. and Western Europe as primary markets, and also operates a joint venture in China; revenue is generated through product sales with reimbursement governed by HCPCS codes and varying by jurisdiction. Cerus manufactures through third-party suppliers and currently holds regulatory approval in the U.S. and Europe for its platelet and plasma systems, with additional products in development including a red blood cell system undergoing regulatory review.